Journal Article

A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern

Townsend, Alain, Langeland, Nina, Jämsén, Anni, Harding, Adam C., Olofsson, Jan Stefan, Sandnes, Helene, Nguyen, Dung, James, William S., Cox, Rebecca Jane, Harvala, Heli, Rijal, Pramila, Schimanski, Lisa, Fjelltveit, Elisabeth, Brokstad, Karl Albert, Ertesvåg, Nina Urke, Roberts, David, Lartey, Sarah, Tan, Tiong Kit, Zambon, Maria, Mohn, Kristin G. I., Sævik, Marianne, Hansen, Lena, Xiao, Julie, Madsen, Anders, Zhou, Fan, Ljostveit, Sonja, Dunachie, Susanna, Øyen, Siri

2022

Overview

Background Evaluation of susceptibility to emerging SARS-CoV-2 variants of concern (VOC) requires rapid screening tests for neutralising antibodies which provide protection. Methods Firstly, we developed a receptor-binding domain-specific haemagglutination test (HAT) to Wuhan and VOC (alpha, beta, gamma and delta) and compared to pseudotype, microneutralisation and virus neutralisation assays in 835 convalescent sera. Secondly, we investigated the antibody response using the HAT after two doses of mRNA (BNT162b2) vaccination. Sera were collected at baseline, three weeks after the first and second vaccinations from older (80–99 years, n  = 89) and younger adults (23–77 years, n  = 310) and compared to convalescent sera from naturally infected individuals (1–89 years, n  = 307). Results Here we show that HAT antibodies highly correlated with neutralising antibodies (R = 0.72–0.88) in convalescent sera. Home-dwelling older individuals have significantly lower antibodies to the Wuhan strain after one and two doses of BNT162b2 vaccine than younger adult vaccinees and naturally infected individuals. Moverover, a second vaccine dose boosts and broadens the antibody repertoire to VOC in naïve, not previously infected older and younger adults. Most (72–76%) older adults respond after two vaccinations to alpha and delta, but only 58–62% to beta and gamma, compared to 96–97% of younger vaccinees and 68–76% of infected individuals. Previously infected older individuals have, similarly to younger adults, high antibody titres after one vaccination. Conclusions Overall, HAT provides a surrogate marker for neutralising antibodies, which can be used as a simple inexpensive, rapid test. HAT can be rapidly adaptable to emerging VOC for large-scale evaluation of potentially decreasing vaccine effectiveness. Plain language summary The aim of this study was to rapidly investigate the immune responses after SARS-CoV-2 infection and vaccination of younger adults and the elderly. Antibodies are proteins produced by the immune system that are released into the bloodstream and help fight infections. A simple method using red blood cells obtained from blood was developed and used to detect antibodies to SARS-CoV-2. This test was able to measure protective antibodies to several variants of concern. The elderly had lower antibody responses after vaccination. Two vaccinations induced a broader antibody response to viral variants, similar to the response induced following Covid-19. This antibody detection method could be used as a finger prick test to rapidly detect specific antibodies to emerging variants and enable quick identification of individuals who might benefit from a booster vaccination. Ertesvåg, Xiao et al. describe a method to evaluate neutralising antibodies to SARS-CoV-2 infection or vaccination, including variants of concern. A second mRNA-vaccine dose results in a broader antibody repertoire in adults, although with reduced cross-reactivity to beta and gamma compared to alpha and delta, particularly in the elderly.

• Publisher: Nature Publishing Group UK,Nature Portfolio
• Subject: 13/1 / 13/106 / 42 / 42/109 / 631/250/255/2514 / 631/326/590/2293 / 692/53/2423 / 82 / 82/1 / Medicine / Medicine & Public Health